About Us
TheraBionic is innovating cancer treatment by using radio frequencies delivered through a proprietary medical device. We are focused on transforming the lives of patients with difficult-to-treat cancers by applying our discoveries in bio-electromagnetics to the targeted experimental treatment of cancer.
We are engaged in clinical trials using radiofrequency electromagnetic fields. Our research has resulted in the discovery of tumor-specific modulation frequencies, which we believe will effectively block the growth of tumor cells without altering non-tumor cells.
We have developed the TheraBionic P1 investigational medical device, a portable device intended for home use. Our goal is to expand the use of the TheraBionic P1 in several other indications, such as breast cancer, prostate cancer, pancreatic cancer, ovarian cancer, cholangiocarcinoma, and brain tumors. We also are investigating the effectiveness of tumor-specific modulation frequencies for early diagnosis of cancer.
Boris Pasche (CEO) and Alexandre Barbault (Board Member), coinventors of TheraBionic technology and cofounders of TheraBionic Inc. (US Delaware Corporation (formerly TheraBionic LLC)) and TheraBionic GmbH (the device manufacturer located in Germany). They had one goal in mind since the beginning of their research: developing better and safer therapies for cancer.
Since 2001, they have developed a proprietary technology as well as proprietary devices to identify tumor-specific modulation frequencies. Identification of these frequencies was based on changes in hemodynamic parameters occurring when patients are exposed to low and safe radiofrequency electromagnetic fields, which are amplitude-modulated from 0.1 Hz to 150 kHz. Using this approach, they discovered that patients with the same tumor type, e.g. hepatocellular carcinoma, had the same hemodynamic changes when exposed to the same frequency modulations.
Following the identification of tumor-specific frequencies, they hypothesized that these frequencies could block cancer growth. They designed and built new investigational devices emitting the same modulation frequencies as those identified in patients. The experimental treatment was administered for 60 minutes 3 times a day. In two separate small clinical studies, results indicate that this experimental treatment was capable of blocking tumor growth in a substantial proportion of patients without causing any side effects of significance.
The vision of TheraBionic’s founders is to further expand their findings using this technology both for diagnosis and experimental treatment of several forms of cancer.
Meet Our Team of Experts
International Team
Boris Pasche, MD PhD
Chief Executive Officer
Board Chair and Co-Founder
Professor Boris C. Pasche is Chairman of the Board and CEO of TheraBionic Inc. and Geschäftsführer of TheraBionic GmbH. He is co-inventor of the TheraBionic technology, cofounder of TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH, companies focused on the commercialization of TheraBionic’s novel technology for the treatment of cancer, with a first European approval for the treatment of advanced hepatocellular carcinoma. Since 2014, Dr. Pasche has served as attending physician at Wake Forest Medical Center, Director of Wake Forest Baptist Comprehensive Cancer Center, and Chairman, Department of Cancer Biology at Wake Forest University. He is the recipient of the Charles L. Spurr Endowed Chair in Cancer Research.
Professor Pasche received his M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and a M.D. degree from the University of Lausanne, Switzerland. Following a postdoctoral fellowship in Dr. Joseph Loscalzo’s lab at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Pasche did a residency in Internal Medicine at the New York Hospital, Cornell Medical Center. He then undertook his clinical training in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center where he did a second postdoctoral fellowship in the lab of Dr. Joan Massagué, Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research. In 2000 he was recruited to Northwestern University, where he spent eight years and established the Cancer Genetics Program, before being recruited by the University of Alabama at Birmingham as the Director of the Division of Hematology/Oncology, and Martha Ann and David L. May Chair in Cancer Research. He also served as the Associate Director for Translational Research and then Deputy Director of the University of Alabama Comprehensive Cancer Center.
Professor Pasche has co-authored more than 120 articles and numerous books and book chapters. He has served on multiple study sections for NCI, ACS, AACR, DOD and the Komen Foundation. He is a recipient of the Ohio State University Human Cancer Genetics Program Commemorative Medal and is an elected member of the American Society for Clinical Investigation (ASCI) and the American Clinical and Climatological Association (ACCA).
Alexandre Barbault
CoInventor
Board Member
Alexandre Barbault is a member of the Board of TheraBionic Inc. and Geschäftsführer of TheraBionic GmbH. He is coinventor of the TheraBionic technology, cofounder of TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH, companies focused on the commercialization of TheraBionic’s novel technology for the treatment of cancer, with a first European approval for the treatment of advanced hepatocellular carcinoma.
Alexandre Barbault received training as a Heilpraktiker at the Technical College of Saarbrücken. Since 2001 he has worked closely with Professor Boris Pasche to develop the TheraBionic technology. He has co-authored 9 peer review articles related to the use of radiofrequency electromagnetic fields, which are amplitude modulated at specific frequencies.
Valerie Pasche, MD
Chief Operating Officer
Valerie Pasche received her MD from the Brody School of Medicine at East Carolina University in Greenville, NC. She received her training in Anesthesiology at the New York Hospital-Cornell Medical Center in New York and at Northwestern University in Chicago. She has extensive experience with medical devices and compliance with FDA guidelines.
Stefan Grant, MD JD MBA
General Counsel
Dr. Grant is a member of the Board of Directors of TheraBionic Inc. and is the General Counsel of TheraBionic Inc. Dr. Grant is admitted to practice in New York and a member of the patent bar and has extensive experience with respect to the acquisition, management, protection and enforcement of intellectual property rights. Previously, while engaged full-time in the private practice of law he represented clients in connection with intellectual property litigation, licensing transactions, product development and M & A transactions. He also spent several years as general counsel of a NASDAQ traded biopharmaceutical company where he also co-led its business development team.
Dr. Grant also is a practicing academic medical oncologist who has co-authored numerous papers and book chapters in the area of thoracic oncology and currently is an Associate Professor of Medicine at Wake Forest School of Medicine, and the Associate Director of Clinical and Translational Research and IP Development and Director of the Clinical Protocol and Data Management service at Wake Forest Baptist Comprehensive Cancer Center.
Dr. Grant holds a medical degree from the University of the Witwatersrand in South Africa and is board certified in internal medicine, medical oncology and hematology, a JD from Fordham University School of Law and an MBA from the Collat School of Business at UAB in Birmingham.